J&J Concerta/methyphenidate adverse events
FDA's Pediatric Advisory Committee will devote a full day to reviewing reports of adverse events with Johnson & Johnson's Concerta and other methylphenidate products on June 30. On June 29, the committee will review adverse event reports for ethinyl estradiol, J&J's Ortho Tri-Cyclen, Bayer's Cipro, Pfizer's Detrol LA, Sanofi-Aventis' Arava, Abbott's Zemplar, AstraZeneca's Zomig and Merck's Trusopt. The committee will also review the Pediatric Ethics Subcommittee's recommendation on a study protocol in newborns on June 29 (see following item). The meeting will be held at the CDER advisory committee conference room at 5630 Fishers Lane in Rockville, Md. beginning at 12:30 p.m. on June 29 and 8 a.m. on June 30 [Editor's Note: To 1watch a webcastor order a video/DVD of this meeting, visit FDAAdvisoryCommittee.com.]...
You may also be interested in...
Following Perrigo’s announcement of a recall of its generic albuterol inhalers in the US, the FDA has commented on the move and has revealed that thousands of complaints have been received over the clogging problem.
New medicines under evaluation at the European Medicines Agency.
Hikma has received another setback on its US application for a generic version of Advair following a minor complete response letter from the FDA. The resulting delay will push back the expected final response date from the agency closer to that expected by rival Cipla, which filed an ANDA earlier this year.